About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Technique Create Personalized Therapies for People with Advanced Cancers

by Iswarya on July 22, 2019 at 6:08 PM
Font : A-A+

New Technique Create Personalized Therapies for People with Advanced Cancers

Being able to recognize targets for adoptive cell therapies is one of the first steps in developing personalized therapies for people with hard-to-treat cancers, reports a new study. The findings of the study are presented at the American Association of Cancer Research.

However, predicting whether a patient will have an immune response to a particular abnormal protein caused by mutations that serve as a new antigen (neoantigen), can be challenging.

Advertisement


Using an ultra-sensitive and high-throughput isolation technology (termed imPACT Isolation Technology®) designed to isolate neoepitope specific T-cells, UCLA researchers were able to characterize and identify the neoantigens driving the antitumor responses in a patient treated with the anti-PD-1 blockade and isolate the T cell receptors responsible for such effect.

BACKGROUND
Using immune checkpoint inhibitors to treat people with metastatic melanoma has helped transform the way people with the most deadly skin cancer are treated.
Advertisement

Despite its success, there are still many people who do not benefit from the treatment. Up until now, adoptive cell therapy, which involves extracting and harvesting T cells from a patient and engineering them in the laboratory, have targeted shared antigens. That restricts many of the people that can potentially be treated with the therapy because not every cancer has the same antigen that needs to be targeted.

Researchers are working to improve methods to identify new targets for these therapies in hopes to develop more effective and personalized therapies.

METHOD
Researchers analyzed T cell responses in two patients with advanced melanoma, one who responded to anti-PD1 therapy and one who did not respond to the therapy.

Using samples collected before and during treatment, the team isolated the T cells, specifically recognizing the mutations on the tumor by using the imPACT Isolation Technology® developed by PACT Pharma. The technology allows researchers to identify the T cells, and their T cell receptors, that have the ability to detect mutations.

After identifying the T cell receptors, they were re-introduced in T cells from peripheral blood using a non-viral genome engineering method to generate new neoantigen-specific T cells that were used to kill melanoma cells from the same patient.

"In the setting of patients treated with anti-PD-1, we identified for the first time, in a high-throughput manner, which neoantigen mutations in the tumor are being targeted by T cells. More importantly, we were able to identify their T cell receptors and demonstrate that they can actually specifically kill the tumor cells," said lead author Cristina Puig-Saus, Ph.D., an associate project scientist in hematology/oncology at the David Geffen School of Medicine at UCLA.

"We hope that a better understanding of the T cell responses that occur after immune checkpoint blockade will guide the design of personalized adoptive T cell therapies."

IMPACT
Uncovering new ways to identify targets for immunotherapies significantly increases the number of patients who will benefit from immunotherapy. The imPACT Isolation Technology® allows researchers to identify the mutation-specific T cells and understand which mutations are inducing responses against tumors.

AUTHORS
The lead author is Cristina Puig-Saus, Ph.D., an associate project scientist in hematology/oncology at the David Geffen School of Medicine at UCLA. The senior author is Antoni Ribas, MD, PhD., director of the tumor immunology program at the UCLA Jonsson Comprehensive Cancer Center and professor of medicine in the David Geffen School of Medicine at UCLA. Thirty-three additional authors are listed in the abstract.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Latest Cancer News

Combination Therapy may Benefit Leukemia Patients
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Technique Create Personalized Therapies for People with Advanced Cancers Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests